Figure 7. Uptake of radioactivity (UOR_RIT) per tissue (Bq) was determined using the values obtained during biodistribution experiments (Figure 6).

(A) ²¹²Pb-35A7 (anti-CEA). (B) ²¹²Pb-Trastuzumab (anti-HER2). (C) Mean absorbed doses for ²¹²Pb-35A7 and ²¹²Pb-Trastuzumab. The total cumulative decay per tissue (Ã_rs) was calculated from the area under each UOR_RIT curve and multiplied by 8.7 MeV (the mean energy emitted at each decay of ²¹²Pb and daughters). The ratio between tumor absorbed dose and blood absorbed dose was 3.2 (²¹²Pb-35A7) and 3.7 (²¹²Pb-Trastuzumab). The tumor-to-organ absorbed doses ratio were 5.2 (liver) and 5.8 (kidney) for ²¹²Pb-35A7 and 3.0 (liver) and 2.1 (kidney) for ²¹²Pb-Trastuzumab.